The project aims to better understand the development of pediatric low-grade gliomas, the most common brain tumors in children. Despite their generally lower aggressiveness, these tumors are highly variable and difficult to treat, often leading to relapses and long-term complications. Using innovative single-cell sequencing technology, the project will investigate how these tumors evolve over time, particularly in response to treatments. It will explore biological changes and mechanisms that contribute to tumor progression and drug resistance. The goal is to develop more personalized and effective treatment strategies to improve the quality of life for affected children.